2025 New Technology Add On Payment. The Future of Digital Payments OSG For more information on FY 2025 new technology add-on payments, specifically regarding the technologies either continuing to receive payments or starting to receive payments, see MAC. For FY 2025, 24 technologies continue to be eligible for new technology add-on payments, and 15 new applications are eligible for new technology add-on payments
New Technology AddOn Payment (NTAP) Updates for FY 2025 from hiacode.com
The cost criterion evaluates whether the cost of the new technology or service exceeds the predefined 75% cost-to-charge thresholds established with the release of the most recent annual IPPS final rule. Both of these medications are gene therapies that have indications for the treatment of sickle cell disease and when used for this purpose their administration qualifies for a significant NTAP.
New Technology AddOn Payment (NTAP) Updates for FY 2025
As such, coders should make it a priority to recognize and assign the codes that report devices, substances and technologies approved for new technology add-on payment. Both of these medications are gene therapies that have indications for the treatment of sickle cell disease and when used for this purpose their administration qualifies for a significant NTAP. Effective October 1, 2024, the EVOQUE™ system has been approved for the new technology add-on payment
New Technology AddOn Payment (NTAP) for Ultromics Advancing HFpEF Diagnosis Ultromics. For FY 2025, 24 technologies continue to be eligible for new technology add-on payments, and 15 new applications are eligible for new technology add-on payments The NTAP is designated primarily for new high-cost services and technologies and there is a criterion to determine which new services and technologies qualify for the additional payment
Artificial Intelligence Applications Today 2025r 2025 Mattie W. Schneider. This year's final rule includes a 2.9 percent increase in overall IPPS payments, an increase in the NTAP percentage from 65 percent to 75 percent for certain gene therapies approved for new technology add-on payments when indicated and used specifically for the treatment of sickle cell disease, and separate IPPS payment for establishing and maintaining access to essential medicines. New Technology Add-on Payments or NTAPs can represent a significant source of reimbursement for hospitals